A clinical study conducted at the University of Pennsylvania has shown that pharmacogenetic testing can significantly reduce adverse events for cancer patients with a genetic predisposition that hinder the metabolism of common chemotherapy drugs. Published today in JCO Precision Oncology , the study also highlights potential strategies to overcome some of the major challenges facing oncology practices when implementing pharmacogenetic testing.

“For too long, the U.S. lagged behind Europe in adopting genetic testing for chemotherapy dosing, but our study shows it’s not only feasible but also critical for patient safety,” said Sony Tuteja, PharmD, MS, director of pharmacogenomics in the Penn Medicine Center for Genomic Medicine and first author of the study. “With up to 1,300 deaths

See Full Page